Resolvins, including D and E series resolvins, are endogenous lipid mediators generated during the resolution phase of acute inflammation from the omega-3 polyunsaturated fatty acids docosahexaenoic acid (DHA) and eicosapentaenoic acid (EPA). Resolvins have potent antiinflammatory and pro-resolution actions in several animal models of inflammation. Recent findings also demonstrate that resolvin E1 and resolvin D1 can each potently dampen inflammatory and postoperative pain. This review focuses on the mechanisms by which resolvins act on their receptors in immune cells and neurons to normalize exaggerated pain via regulation of inflammatory mediators, transient receptor potential (TRP) ion channels, and spinal cord synaptic transmission. Resolvins may offer novel therapeutic approaches for preventing and treating pain conditions associated with inflammation.
Introduction
Tissue injury results in inflammation and inflammatory pain, such as pain associated with arthritis, temporomandibular joint (TMJ) disorder, lower back injury and surgery. Inflammatory and postoperative pains are typically characterized by heat and mechanical hyperalgesia, increased response to noxious heat and mechanical stimuli, and mechanical allodynia in which a nociceptive response occurs to normally innocuous mechanical stimulus such as light touch [1] [2] [3] [4] . It is generally believed that inflammatory and postoperative pain can manifest as an expression of neuronal plasticity characterized by peripheral sensitization of primary sensory neurons in the dorsal root ganglion (DRG) and trigeminal ganglion [4] [5] [6] and central sensitization of spinal dorsal horn and cortical neurons [1, 7, 8] . Although neuropathic pain after nerve injury and certain surgical procedures, such as amputation and thoracotomy [9] , also engage the mechanisms of peripheral and central sensitization, this review focuses on the mechanisms and potential treatments of tissue-injury-induced inflammatory pain and postoperative pain.
Peripheral sensitization is induced by inflammatory mediators released after tissue insults, such as bradykinin, prostaglandins, H + , nerve growth factors (NGF), proinflammatory cytokines [such as tumor necrosis factor (TNF)-a, interleukin (IL)-1b and IL-6] and proinflammatory chemokines (such as chemokine CC-motif ligand, CCL2) [10] [11] [12] [13] . Notably, the peripheral terminals of nociceptors express the receptors for all these inflammatory mediators [14] . Activation of these receptors causes hyperactivity of key transduction molecules, such as transient receptor potential subtype V1 (TRPV1) and A1 (TRPA1), and conduction molecules such as sodium channels Nav1.7, 1.8 and 1.9. As a result, the sensitivity and excitability of nociceptors are increased via activation of protein kinases, such as protein kinase A (PKA), protein kinase C (PKC) and mitogen-activated protein kinases (MAPKs) [2, 6, [13] [14] [15] [16] [17] .
Tissue injury-triggered hyperactivity of nociceptors leads to increased release of neurotransmitters (e.g. glutamate) and neuromodulators [e.g. substance P and brain-derived neurotrophic factor (BDNF)] from nociceptor central terminals in the spinal cord, which leads to hyperactivity of postsynaptic dorsal horn neurons (i.e. central sensitization) [8] . Activation of NMDA receptors plays an essential role in the induction and maintenance of central sensitization [18] [19] [20] . Central sensitization is important in the maintenance of persistent pain and the generation of secondary pain outside the initial injury site [7, 8, 20] . Phosphorylation of extracellular signal-regulated kinase (pERK), a MAPK family member, in dorsal horn neurons is nociceptive-specific and serves as a marker for central sensitization [21, 22] . Accordingly, pERK plays a crucial role in the induction and maintenance of central sensitization by increasing NMDA receptor activity, inhibiting Kv4.2 potassium channel activity, and inducing AMPA receptor trafficking and transcription of pronociceptive genes [19, 21, 23] . Recent progress also points to an important role of glial cells, such as microglia and astrocytes, in the spinal cord and brain for the genesis of central sensitization linked to the development of inflammatory and postoperative pain [24] [25] [26] [27] [28] [29] [30] [31] [32] . Tissue injury produces TNF-a and IL-1b in spinal microglia and astrocytes, which drive central sensitization by increasing excitation and decreasing inhibition in dorsal horn neurons [33] [34] [35] . In addition, descending facilitation from the cortex and brain stem contributes to persistent pain states after tissue injury [36, 37] . In this review, we discuss how novel pro-resolving lipid mediators, namely resolvins, can reduce tissue injuryinduced inflammatory and postoperative pain, as well as tissue injury-induced peripheral and central sensitization. 
